Omni Bridgeway Funding New Zealand Class Action Against Johnson & Johnson
For consumers who were unwittingly deceived by falsely advertised products, a well-funded class action remains one of the few options available for these individuals to seek justice and compensation.
Reporting by The Post covers a new class action filed in the High Court of New Zealand, which is being brought against Johnson & Johnson over the alleged sale of ineffective cold and flu medications. The lawsuit alleges that Johnson & Johnson manufactured cold and flu products containing Penylephrine, which some medical studies have found is not an effective oral treatment for nasal congestion. Eligibility for the class action includes consumers in New Zealand who purchased one of the 17 identified Codral, Sudafed or Benadryl branded products between 2005 and 2025.
The class action has been brought by Australian law firm JGA Saddler, with litigation funding provided by Omni Bridgeway. This is the second such lawsuit brought against Johnson & Johnson by this team, with JGA and Omni having worked together to bring a similar class action against the pharmaceutical giant in 2024.
Rebecca Jancauskas, director at JGA Saddler, argues that “Johnson & Johnson has misled the public and they need to be held accountable for their actions.” Furthermore, Jancauskas suggests that there may be a larger pool of affected customers in New Zealand than Australia, explaining that between 2011 and 2024 “there was no other alternative for consumers in New Zealand suffering from sinus symptoms or allergy symptoms or cold and flu symptoms.”
Additional information on the class action can be found on Omni Bridgeway’s website.







